PDF(1585 KB)
不同血小板水平儿童急性淋巴细胞白血病的临床特征及预后研究
张傲利, 陈晓娟, 邹尧, 杨文钰, 郭晔, 王书春, 张丽, 刘晓明, 阮敏, 刘天峰, 戚本泉, 竺晓凡
中国当代儿科杂志 ›› 2019, Vol. 21 ›› Issue (8) : 766-771.
PDF(1585 KB)
PDF(1585 KB)
不同血小板水平儿童急性淋巴细胞白血病的临床特征及预后研究
Clinical features and prognosis of children with acute lymphoblastic leukemia and different platelet levels
目的 探讨儿童急性淋巴细胞白血病（ALL）初诊时不同血小板水平与预后的相关性。方法 选取采用中国儿童白血病协作组-ALL 2008（CCLG-ALL 2008）方案治疗的892例初诊ALL患儿为研究对象，按初诊时血小板水平分为血小板正常组（血小板≥ 100×109/L，n=263）和血小板减少组（血小板 < 100×109/L，n=629）；血小板减少组又分为（50~）×109/L（n=243）、（20~）×109/L（n=263）、 < 20×109/L（n=123）亚组。对各组患儿的性别、年龄、免疫分型、分子生物学等临床特征与无事件生存（EFS）率、总生存（OS）率的相关性进行分析。结果 血小板正常组MLL基因重排阳性、复发率低于血小板减少组（P < 0.05），血小板正常组10年预期EFS率高于血小板减少组（P < 0.05），两组10年预期OS率差异无统计学意义（P > 0.05）；剔除MLL基因重排阳性患儿，血小板正常组10年预期EFS率仍高于血小板减少组（P < 0.05），两组10年预期OS率差异仍无统计学意义（P > 0.05）。血小板 < 20×109/L亚组10年预期EFS率和10年预期OS率低于血小板正常组、（50~）×109/L亚组、（20~）×109/L亚组（P < 0.05）；剔除MLL基因重排阳性患儿，血小板 < 20×109/L亚组10年预期EFS率和10年预期OS率仍低于血小板正常组、（50~）×109/L亚组、（20~）×109/L亚组（P < 0.05）。结论 伴有MLL基因重排阳性的ALL患儿临床表现多为血小板减少。ALL患儿初诊时血小板水平与患儿预后相关，血小板计数正常者复发率低、预后好，血小板 < 20×109/L组预后最差。
Objective To study the association of platelet level at diagnosis with prognosis in children with acute lymphoblastic leukemia (ALL). Methods A total of 892 children with ALL who underwent chemotherapy with the CCLG-ALL 2008 regimen were enrolled. According to the platelet count at diagnosis, these children were divided into normal platelet count group (platelet count ≥ 100×109/L; n=263) and thrombocytopenia group (platelet count < 100×109/L; n=629). The thrombocytopenia group was further divided into (50- < 100)×109/L (n=243), (20- < 50)×109/L (n=263), and < 20×109/L (n=123) subgroups. The association of clinical features (sex, age, immunophenotype, and molecular biology) with event-free survival (EFS) and overall survival (OS) was analyzed. Results Compared with the thrombocytopenia group, the normal platelet count group had significantly lower positive rate of MLL gene rearrangement and recurrence rate (P < 0.05), as well as a significantly higher 10-year EFS rate (P < 0.05). There was no significant difference in 10-year OS between the two groups (P > 0.05). The normal platelet count group still had a significantly higher 10-year EFS rate than the thrombocytopenia group after the children with MLL gene rearrangement were excluded (P < 0.05), and there was still no significant difference in 10-year OS between the two groups (P > 0.05). The < 20×109/L subgroup had significantly lower 10-year EFS and OS rates than the normal platelet count group, the (50- < 100)×109/L subgroup, and the (20- < 50)×109/L subgroup (P < 0.05). After the children with MLL gene rearrangement were excluded, the < 20×109/L subgroup still had significantly lower 10-year EFS and OS rates than the normal platelet count group, the (50- < 100)×109/L subgroup, and the (20- < 50)×109/L subgroup (P < 0.05). Conclusions ALL children with MLL gene rearrangement often have the clinical manifestation of thrombocytopenia. Platelet level at diagnosis is associated with the prognosis of ALL children. The children with normal platelet count have a low recurrence rate and good prognosis, and those with a platelet count of < 20×109/L have the worst prognosis.
急性淋巴细胞白血病 / 血小板计数 / 预后 / 复发 / 儿童
Acute lymphoblastic leukemia / Platelet count / Prognosis / Recurrence / Child
[1] Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(2):83-103.
[2] Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia[J]. Pediatr Int, 2018, 60(1):4-12.
[3] Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia[J]. Lancet, 2013, 381(9881):1943-1955.
[4] Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005:a report from the children's oncology group[J]. J Clin Oncol, 2012, 30(14):1663-1669.
[5] Pieters R, de Groot-Kruseman H, Van der Velden V, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring:study ALL10 from the Dutch Childhood Oncology Group[J]. J Clin Oncol, 2016, 34(22):2591-2601.
[6] Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia:results of the randomized intercontinental trial ALL IC-BFM 2002[J]. J Clin Oncol, 2014, 32(3):174-184.
[7] Faderl S, Thall PF, Kantarjian HM, et al. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission[J]. Br J Haematol, 2002, 117(4):869-874.
[8] 凌婧, 高静, 周雪梅, 等.初诊儿童急性淋巴细胞白血病血小板计数与预后的关系研究[J]. 中国血液流变学杂志, 2017, 27(3):247-250.
[9] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 第3版. 北京:科学出版社, 2008:116-121.
[10] Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008:the first nation-wide prospective multicenter study in China[J]. Am J Hematol, 2018, 93(7):913-920.
[11] Yokoyama A. Transcriptional activation by MLL fusion proteins in leukemogenesis[J]. Exp Hematol, 2017, 46:21-30.
[12] Behm FG, Raimondi SC, Frestedt JL, et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age[J]. Blood, 1996, 87(7):2870-2877.
[13] Marschalek R. MLL leukemia and future treatment strategies[J]. Arch Pharm (Weinheim), 2015, 348(4):221-228.
[14] Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment[J]. Br J Haematol, 2014, 164(6):767-778.
[15] Ruscetti FW, Akel S, Bartelmez SH. Autocrine transforming growth factor-β regulation of hematopoiesis:many outcomes that depend on the context[J]. Oncogene, 2005, 24(37):5751-5763.
[16] Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes[J]. Thromb Res, 2002, 108(2-3):139-145.
[17] Verheul HM, Pinedo HM. Tumor growth:a putative role for platelets?[J]. Oncologist, 1998, 3(2):Ⅱ.
[18] Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma[J]. Cytokine Growth Factor Rev, 2004, 15(4):275-286.
[19] Gupta GP, Massagué J. Platelets and metastasis revisited:a novel fatty link[J]. J Clin Invest, 2004, 114(12):1691-1693.
[20] Stanger BZ, Kahn ML. Platelets and tumor cells:a new form of border control[J]. Cancer Cell, 2013, 24(1):9-11.
[21] Qian X, Wen-jun L. Platelet changes in acute leukemia[J]. Cell Biochem Biophys, 2013, 67(3):1473-1479.
